Andrew Xuan Vinh Tran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrew Xuan Vinh Tran has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Jasmine Thuy Tran
3 shared publicationsMichael Joseph Diaz
3 shared publications- Brandon Lucke-Wold
Department of Neurosurgery, University of Arizona, Tucson, AZ 85721, USA
2 shared publications - Jasmine Thuy Tran
School of Medicine, University of Indiana, Indianapolis, IN 46202, USA
2 shared publications Kamil Taneja
2 shared publicationsKaran Patel
2 shared publications
Latest Publications
- Open Access
- 17 July 2023
- Published by Wiley in International Journal of Dermatology
- Vol. 62 (12) , 1489-1491
Subcutaneous mass of the forearm
- 17 July 2023
- Published by Wiley in International Journal of Dermatology
- Vol. 62 (12) , 1489-1491
Open AccessSubcutaneous mass of the forearm
- Open Access
Melanoma Brain Metastases: A Systematic Review of Opportunities for Earlier Detection, Diagnosis, and Treatment
Introduction: Melanoma continues to represent the most serious skin cancer worldwide. However, few attempts have been made to connect the body of research on advanced melanoma. In the present review, we report on strides made in the diagnosis and treatment of intracranial metastatic melanoma. Methods: Relevant Cochrane reviews and randomized-controlled trials published by November 2022 were systematically retrieved from the Cochrane Library, EMBASE, and PubMed databases (N = 27). Search and screening methods adhered to the 2020 revision of the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. Results: Although the research surrounding the earlier detection of melanoma brain metastasis is scarce, several studies have highlighted specific markers associated with MBM. Such factors include elevated BRAFV600 mutant ctDNA, high LDH concentration, and high IGF-1R. The approach to treating MBM is moving away from surgery and toward nonsurgical management, namely, a combination of stereotactic radiosurgery (SRS) and immunotherapeutic agents. There is an abundance of emerging research seeking to identify and improve both novel and established treatment options and diagnostic approaches for MBM, however, more research is still needed to maximize the clinical efficacy, especially for new immunotherapeutics. Conclusions: Early detection is optimal for the efficacy of treatment and MBM prognosis. Current treatment utilizes chemotherapies and targeted therapies. Emerging approaches emphasize biomarkers and joint treatments. Further exploration toward preliminary identification, the timing of therapies, and methods to ameliorate adverse treatment effects are needed to advance MBM patient care.
Open AccessMelanoma Brain Metastases: A Systematic Review of Opportunities for Earlier Detection, Diagnosis, and Treatment
Introduction: Melanoma continues to represent the most serious skin cancer worldwide. However, few attempts have been made to connect the body of research on advanced melanoma. In the present review, we report on strides made in the diagnosis and treatment of intracranial metastatic melanoma. Methods: Relevant Cochrane reviews and randomized-controlled trials published by November 2022 were systematically retrieved from the Cochrane Library, EMBASE, and PubMed databases (N = 27). Search and screening methods adhered to the 2020 revision of the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. Results: Although the research surrounding the earlier detection of melanoma brain metastasis is scarce, several studies have highlighted specific markers associated with MBM. Such factors include elevated BRAFV600 mutant ctDNA, high LDH concentration, and high IGF-1R. The approach to treating MBM is moving away from surgery and toward nonsurgical management, namely, a combination of stereotactic radiosurgery (SRS) and immunotherapeutic agents. There is an abundance of emerging research seeking to identify and improve both novel and established treatment options and diagnostic approaches for MBM, however, more research is still needed to maximize the clinical efficacy, especially for new immunotherapeutics. Conclusions: Early detection is optimal for the efficacy of treatment and MBM prognosis. Current treatment utilizes chemotherapies and targeted therapies. Emerging approaches emphasize biomarkers and joint treatments. Further exploration toward preliminary identification, the timing of therapies, and methods to ameliorate adverse treatment effects are needed to advance MBM patient care.
- Open Access
- 19 January 2023
- Published by JMIR Publications Inc. in JMIR Preprints
The financial burden of facial cellulitis: an exploratory study of associated factors (Preprint)
UNSTRUCTURED N/A - Research Letter
- 19 January 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe financial burden of facial cellulitis: an exploratory study of associated factors (Preprint)
UNSTRUCTURED N/A - Research Letter
- Open Access
- 19 January 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Medicare payment amounts for cellulitis in the inpatient setting across the United States: a state-by-state analysis (Preprint)
UNSTRUCTURED N/A - Research Letter
- 19 January 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessMedicare payment amounts for cellulitis in the inpatient setting across the United States: a state-by-state analysis (Preprint)
UNSTRUCTURED N/A - Research Letter
- Open Access
- 19 January 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Medicare reimbursement rates for pre-malignant lesion removal have fallen significantly from 2007 to 2022 (Preprint)
UNSTRUCTURED N/A - Research Letter
- 19 January 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessMedicare reimbursement rates for pre-malignant lesion removal have fallen significantly from 2007 to 2022 (Preprint)
UNSTRUCTURED N/A - Research Letter
- Open Access
Primary and Metastatic Cutaneous Melanomas Discriminately Enrich Several Ligand-Receptor Interactions
Introduction: Cutaneous melanoma remains a leading cancer with sobering post-metastasis mortality rates. To date, the ligand-receptor interactome of melanomas remains weakly studied despite applicability to anti-cancer drug discovery. Here we leverage established crosstalk methodologies to characterize important ligand-receptor pairs in primary and metastatic cutaneous melanoma. Methods: Bulk transcriptomic data, representing 470 cutaneous melanoma samples, was retrieved from the Broad Genome Data Analysis Center Firehose portal. Tumor and stroma compartments were computationally derived as a function of tumor purity estimates. Identification of preferential ligand-receptor interactions was achieved by relative crosstalk scoring of 1380 previously established pairs. Results: Metastatic cutaneous melanoma uniquely enriched PTH2-PTH1R for tumor-to-stroma signaling. The Human R-spondin ligand family was involved in 4 of the 15 top-scoring stroma-to-tumor interactions. Receptor ACVR2B was involved in 3 of the 15 top-scoring tumor-to-tumor interactions. Conclusions: Numerous gene-level differences in ligand-receptor crosstalk between primary and metastatic cutaneous melanomas. Further investigation of notable pairings is warranted.
Open AccessPrimary and Metastatic Cutaneous Melanomas Discriminately Enrich Several Ligand-Receptor Interactions
Introduction: Cutaneous melanoma remains a leading cancer with sobering post-metastasis mortality rates. To date, the ligand-receptor interactome of melanomas remains weakly studied despite applicability to anti-cancer drug discovery. Here we leverage established crosstalk methodologies to characterize important ligand-receptor pairs in primary and metastatic cutaneous melanoma. Methods: Bulk transcriptomic data, representing 470 cutaneous melanoma samples, was retrieved from the Broad Genome Data Analysis Center Firehose portal. Tumor and stroma compartments were computationally derived as a function of tumor purity estimates. Identification of preferential ligand-receptor interactions was achieved by relative crosstalk scoring of 1380 previously established pairs. Results: Metastatic cutaneous melanoma uniquely enriched PTH2-PTH1R for tumor-to-stroma signaling. The Human R-spondin ligand family was involved in 4 of the 15 top-scoring stroma-to-tumor interactions. Receptor ACVR2B was involved in 3 of the 15 top-scoring tumor-to-tumor interactions. Conclusions: Numerous gene-level differences in ligand-receptor crosstalk between primary and metastatic cutaneous melanomas. Further investigation of notable pairings is warranted.